<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is the most important identifiable risk factor for the progression to esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This article reviews the current endoscopic therapies for BE with high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and intramucosal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and briefly discusses the endoscopic palliation of advanced <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: The diagnosis of low-grade or high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (HGD) is based on several cytologic criteria that suggest <z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">neoplastic transformation</z:e> of the columnar epithelium </plain></SENT>
<SENT sid="3" pm="."><plain>HGD and <z:mp ids='MP_0002038'>carcinoma</z:mp> in situ are regarded as equivalent </plain></SENT>
<SENT sid="4" pm="."><plain>The presence of <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, particularly HGD, is also a risk factor for synchronous and metachronous <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_589'>Dysplasia</z:mpath> is a marker of <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and also has been shown to be the preinvasive lesion </plain></SENT>
<SENT sid="6" pm="."><plain>Esophagectomy has been the conventional treatment for T1 <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> and, although debated, is an appropriate option in some patients with HGD due to the presence of occult <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in over one-third of patients </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: Endoscopic ablative modalities (eg, photodynamic therapy and cryoablation) and endoscopic resection techniques (eg, endoscopic mucosal resection) have demonstrated promising results </plain></SENT>
<SENT sid="8" pm="."><plain>The significant morbidity and mortality of esophagectomy makes endoscopic treatment an attractive potential option </plain></SENT>
</text></document>